BDTX blackdiamondtherapeutics.com: Enterprise Value to EBITDA Ratio

This chart shows that the market EV/EBITDA for Black Diamond (BDTX) is 0.00, confirming the resilience of its small-molecule patents and the success of the MasterKey system in combating EGFR mutations. The business relies on ESG standards, optimizing the energy consumption of its IT infrastructure and strictly adhering to bioethics. However, geopolitical fragmentation complicates the procurement of biomaterials and the execution of global clinical trials for new drugs under current sanctions.

BDTX (Black Diamond Therapeutics, Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/12/2026

Comprehensive metric breakdowns and analytics for blackdiamondtherapeutics.com (BDTX)

- stock price and consensus target price:

Stock Quotes Black Diamond Therapeutics Inc.|BDTX - Average Forecast Price

- company stock capitalization data:

Market Valuation Black Diamond Therapeutics, Inc|BDTX - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share Black Diamond|BDTX - Total Net Assets|Market Capitalization to Book Value Ratio blackdiamondtherapeutics.com|BDTX - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

BDTX - Company Net Income|Projected Future Earnings Black Diamond|BDTX - Price to Earnings Multiple|Projected Price to Earnings Black Diamond|BDTX - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Black Diamond Therapeutics, Inc|BDTX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Black Diamond|BDTX - Earnings per share for the trailing year|Quarterly EPS earnings growth blackdiamondtherapeutics.com|BDTX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Black Diamond

Basic company analysis:Black Diamond Therapeutics Inc. BDTX

Original product of blackdiamondtherapeutics.com

The metric's formula is highly sensitive to the quality of operating profit and the volume of debt load. The ratio compares the total enterprise value to its EBITDA, revealing the real value of the business net of leverage. For Black Diamond (BDTX), this calculation remains stable, as the humanitarian status of medicine and the US legal framework eliminate sanction risks. By analyzing the current EV/EBITDA level of Black Diamond (BDTX), an investor can accurately assess the asset's creditworthiness.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|ORIC (ORIC Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Relay Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nurix Therapeutics (NRIX)|TYRA (tyra.bio) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VSTM (Verastem)|Enterprise Value to EBITDA Multiple Monte Rosa Therapeutics Inc|Cullinan Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Immuneering Corp.|CCCC (C4 Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|RPTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (PMV Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple